Sammy Elmariah

MD MPH

Interventional cardiologist
Chief, Interventional Cardiology
Medical Director, Cardiac Catheterization Laboratory
Heart valve specialist, proud husband and father

About me

Dr. Sammy Elmariah is an interventional cardiologist who cares for adults with heart valve disease, coronary artery disease and congenital heart disease. He is an expert in transcatheter (minimally invasive) heart valve procedures, including transcatheter aortic valve replacement (TAVR), transcatheter edge-to-edge mitral valve repair (TEER or MitraClip) and transcatheter mitral valve replacement (TMVR). He also specializes in assessing new medical devices for repairing or replacing the heart's tricuspid valve.

The overall goal of Elmariah's research is to advance transcatheter and other surgical procedures for heart valve disease in order to maximize patient health and outcomes. He leads several clinical trials (studies with human volunteers) focused on valvular heart disease. These include landmark studies testing new transcatheter devices that treat heart valve disease without the need for open heart surgery. He and his research team are also investigating how to increase access to heart valve disease treatments and improve patient involvement in the management of their own care. And they are studying biomarkers (distinctive, measurable substances) in the blood that may help doctors determine the optimal time for individual patients to undergo heart valve procedures. His research team is funded by the National Institutes of Health, American Heart Association, U.S. Department of Defense and several industry partners.

Elmariah earned his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed a residency in internal medicine at the Hospital of the University of Pennsylvania. He completed fellowships in interventional cardiology and structural heart disease at Massachusetts General Hospital, an affiliate of Harvard Medical School. He also has a master of public health degree from the Harvard T.H. Chan School of Public Health.

Dr. Sammy Elmariah is married to Dr. Sarina Elmariah, a dermatologist at UCSF, and they are the proud parents of two wonderful boys.

  • Education

    University of Pennsylvania, MD, 2002

  • Residencies

    University of Pennsylvania, Internal Medicine, 2005

  • Fellowships

    Harvard Medical School, Interventional Cardiology, 2011

    Harvard Medical School, Structural Heart Disease, 2012

  • Academic Title

    Associate Professor

Listening to my patients' desires and fears motivates me to provide compassionate and personalized care and inspires my research and innovation.

Conditions I specialize in

Treatments I provide

Where I see patients (2)

    My reviews

    4.9

    Overall Experience
    60 Ratings
    About our process
    Nov 10, 2024
    I have not received instructions from my visit. Will I?
    Sep 14, 2024
    Cardiology is a team effort with good communication. Dr Elmariah is beyond attentive and caring. I had a very successful recovery, that's great but I will miss him! I realized I wanted to share my appreciation, truly thankful for 'Wilbur' my new valve.
    Aug 24, 2024
    Excellent!
    Jun 18, 2024
    Everybody was so wonderful. They listened to all our concerns and made us feel that this heart problem could be resolved. And WOW I have a team. Every doctor we met was so reassuring We know I'm in very good hands. Am anxiously waiting for the phone call to make arrangements for my procedure. I'm nervous, but know I'll be well taken care of by my Team.
    Mar 24, 2024
    Dr Sammy explained perfectly
    Mar 12, 2024
    Dr. Elmariah and Dr. Lima were terrific
    Dec 10, 2023
    Exceptional!
    Nov 20, 2023
    I felt as though I was the only patient they had. The care and concern I received was such a comfort. Gave me great confidence in my provieder.
    Aug 12, 2023
    Dr. Elmariah was very compassionate and patient in listening to my concerns and explaining everything to me.
    Jul 31, 2023
    I found Dr. Elmariah exceptionally responsive, informative, and concerned with me as a person. This was true of his whole team.
    May 27, 2023
    Best service
    Mar 04, 2023
    Good listener, understood my specific issues affecting my risks, future issues. Respectful, efficient yet unhurried.

    Selected research

    See all research
    Decorative Caduceus

    MitraClip REPAIR MR Study

    The proportion of subjects who are alive, without stroke, CV hospitalization or acute kidney injury requiring renal replacement therapy at 2 years in the Device and Control groups, respectively

    Recruiting

    Decorative Caduceus

    Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

    Comparison of number of participants with composite endpoint events between experimental and active comparator arms

    Recruiting

    Decorative Caduceus

    GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent...

    Proportion of subjects with recurrent ischemic stroke post study device implant

    Recruiting

    Decorative Caduceus

    Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

    Recruiting

    Decorative Caduceus

    Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY...

    Composite score of all-cause mortality, valve re-intervention, hospitalizations and urgent visits for heart failure, or onset of ≥ 3+ MR (by transthoracic echocardiogram (TTE)) from randomization to a minimum follow-up of 3 years ...

    Recruiting

    Decorative Caduceus

    A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on...

    To demonstrate the superiority of pelacarsen (TQJ230) vs. placebo in slowing the progression of calcific aortic valve stenosis by evaluating the change from baseline to month 36 in peak aortic jet velocity by echocardiography

    Recruiting

    Decorative Caduceus

    SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncont...

    The Primary endpoint of office Systolic Blood Pressure (SBP) change at 6 months will be assessed for all patients in the Main Study Cohort

    Recruiting

    Contact me

    Share